无症状心衰风险患者心肌功能障碍的演变
研究纳入982例至少有一种心衰危险因素(高血压、肥胖或2型糖尿病)的社区人群,分为2型糖尿病组(431例)和非2型糖尿病组(551例),基线及中位19个月随访时行超声心动图检查。2型糖尿病组全球纵向应变(GLS)随访较基线降低(-17.8±2.6% vs -17.4±2.8%,p=0.003),非2型糖尿病组无变化;两组估测左室充盈压均升高;倾向匹配后二甲双胍与e'变化较小(β=0.58,95%CI 0.13~1.03,p=0.013)及E/e'变化较小(β=-0.96,95%CI -1.66~-0.26,p=0.007)相关,但与GLS变化无关(p=0.46)。
要点
- 无症状2型糖尿病合并心衰危险因素患者随访约2年出现GLS和左室充盈压恶化。
- 非2型糖尿病组GLS无显著变化,但估测左室充盈压亦升高。
- 倾向匹配后二甲双胍与e'和E/e'恶化较少相关,与GLS变化无关。
关键影像表现/征象
- 2型糖尿病组GLS随访较基线降低(基线-17.8±2.6% vs 随访-17.4±2.8%,p=0.003)。
- 非2型糖尿病组GLS随访较基线无显著变化(-18.7±2.7% vs -18.6±3.0%,p=0.41)。
- 估测左室充盈压在2型糖尿病组(p=0.001)和非2型糖尿病组(p=0.04)均升高。
- 二甲双胍治疗的2型糖尿病患者估测左室充盈压未升高(E/e'基线8.9±2.7 vs 随访9.1±2.7,p=0.485),e'无变化(7.6±1.5 cm/s vs 7.6±1.8 cm/s,p=0.88)。
- 倾向匹配后,二甲双胍与e'变化较小(β=0.58,95%CI 0.13至1.03,p=0.013)和E/e'变化较小(β=-0.96,95%CI -1.66至-0.26,p=0.007)相关,但与GLS变化无关(p=0.46)。
诊断标准与关键数值
- GLS以超声心动图测量,2型糖尿病组随访较基线降低(-17.8±2.6% vs -17.4±2.8%,p=0.003),非2型糖尿病组无显著变化(-18.7±2.7% vs -18.6±3.0%,p=0.41)。
- 估测左室充盈压以E/e'评估,2型糖尿病组随访较基线升高(p=0.001),非2型糖尿病组亦升高(p=0.04)。
- 二甲双胍治疗后E/e'基线8.9±2.7 vs 随访9.1±2.7(p=0.485),e'基线7.6±1.5 cm/s vs 随访7.6±1.8 cm/s(p=0.88)。
- 倾向匹配后二甲双胍与e'变化β=0.58(95%CI 0.13至1.03,p=0.013)及E/e'变化β=-0.96(95%CI -1.66至-0.26,p=0.007)相关,与GLS变化无关(p=0.46)。
临床应用与阅片要点
- 对无症状2型糖尿病合并心衰危险因素患者,超声心动图GLS和E/e'可用于监测心肌功能障碍进展。
- 二甲双胍使用与左室充盈压和心肌松弛恶化较少相关,但与收缩功能无关;作者结论为观察性关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The determinants of changes in systolic and diastolic parameters in patients age >65 years, at risk of heart failure (HF), and with and without asymptomatic type 2 diabetes mellitus (T2DM) was assessed by echocardiography. The association between metformin and myocardial function was also assessed.
BACKGROUND: The increasing prevalence of T2DM will likely further fuel the epidemic of HF. Understanding the development or progression of left ventricular (LV) dysfunction may inform effective measures for HF prevention.
METHODS: A total of 982 patients with at least one HF risk factor (hypertension, obesity, or T2DM) were recruited from 2 community-based populations and divided into 2 groups: T2DM (n = 431, age 71 ± 4 years) and non-T2DM (n = 551, age 71 ± 5 years). Associations of metformin therapy were evaluated in the T2DM group. All underwent a comprehensive echocardiogram, including global longitudinal strain (GLS) and diastolic function (transmitral flow [E], annular velocity [e']) at baseline and follow-up (median 19 months [interquartile range: 17 to 26 months]). Comparisons were facilitated by propensity matching.
RESULTS: A reduction in GLS was observed in the T2DM group (baseline -17.8 ± 2.6% vs. follow-up -17.4 ± 2.8%; p = 0.003), but not in the non-T2DM group (-18.7 ± 2.7% vs. -18.6 ± 3.0%; p = 0.41). Estimated LV filling pressures increased in both the T2DM group (p = 0.001) and the non-T2DM group (p = 0.04). Metformin-treated patients with T2DM did not increase estimated LV filling pressure (E/e' baseline 8.9 ± 2.7 vs. follow-up 9.1 ± 2.7; p = 0.485) or change e' (7.6 ± 1.5 cm/s vs. 7.6 ± 1.8 cm/s; p = 0.88). After propensity matching, metformin was associated with a smaller change in e' (β = 0.58 [95% CI: 0.13 to 1.03]; p = 0.013) and E/e' (β = -0.96 [95% CI: -1.66 to -0.26]; p = 0.007) but was not associated with a change in GLS (p = 0.46).
CONCLUSIONS: Over 2 years, there is a worsening of GLS and LV filling pressures in asymptomatic diabetic patients with HF risk factors. Metformin use is associated with less deterioration of LV filling pressures and myocardial relaxation but had no association with systolic function.
引用
- Halabi A, Yang H, Wright L, et al. Evolution of Myocardial Dysfunction in Asymptomatic Patients at Risk of Heart Failure. JACC Cardiovasc Imaging. 2020. PMID: 33221236. doi:10.1016/j.jcmg.2020.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。